Breaking News, Collaborations & Alliances

CytoSen, KBI Launch Strategic PartnershiP

To manufacture therapeutic Natural Killer (NK) cells using a proprietary and scalable, closed system manufacturing process

CytoSen Therapeutics and KBI Biopharma announced a strategic partnership to manufacture therapeutic Natural Killer (NK) cells using a proprietary and scalable, closed system manufacturing process.    As part of the initial collaboration, KBI will manufacture the NK cell product in its The Woodlands, Texas facility for CytoSen’s planned Phase 2 trial evaluating lead candidate CSTD002-NK in high risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) patients undergoing haploid...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters